CRMD CorMedix Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%
Returns
ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $54.52M | $101.93M | $127.43M | $131.34M | $101.55M | $39.74M | $39.08M | $31.21M |
| Cost of revenue | $14.21M | $14.51M | $12.01M | $11.17M | $7.57M | $1.81M | $1.54M | $1.12M |
| Gross profit | $30.00M | $77.13M | $105.12M | $107.31M | $93.08M | $37.87M | $37.48M | $30.03M |
| R&D expense | $7.04M | $6.68M | $7.21M | $8.60M | $5.10M | $2.44M | $3.19M | $1.73M |
| SG&A expense | $17.90M | $15.09M | $21.72M | $23.57M | $25.45M | $9.50M | $9.69M | $7.11M |
| Operating income | -$6.62M | $42.91M | $63.66M | $59.13M | $51.35M | $19.54M | $20.12M | $12.94M |
| Interest expense | — | — | — | $1.82M | $948,242 | $6,671 | $10,007 | $10,007 |
| Pretax income | -$16.45M | $38.73M | $55.65M | $56.45M | $52.58M | $20.35M | $20.64M | $13.46M |
| Income tax | -$1.73M | $12.74M | $17.04M | $42.43M | -$55.99M | $522,000 | $0 | $0 |
| Net income | -$14.72M | $25.99M | $38.60M | $14.02M | $108.56M | $19.83M | $20.64M | $13.46M |
| EBITDA | $3.91M | $53.45M | $74.20M | $59.42M | $55.14M | $19.71M | $20.29M | $13.02M |
| EPS (basic) | -0.19 | 0.33 | 0.48 | — | 1.42 | 0.29 | 0.32 | — |
| EPS (diluted) | -0.19 | 0.29 | 0.43 | — | 1.26 | 0.28 | 0.30 | — |
| Weighted avg. shares (diluted) | 78.45M | 92.48M | 92.98M | — | 86.21M | 71.92M | 68.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $355.15M | $256.69M | $178.09M | $144.84M | $48.49M | $159.31M | $66.29M | $40.76M |
| Short-term investments | $0 | $0 | $0 | $3.69M | $7.22M | $31.40M | $11.22M | $11.04M |
| Receivables | $76.71M | $161.31M | $154.81M | $171.23M | $158.57M | $42.91M | $54.61M | $51.65M |
| Inventory | $43.14M | $38.58M | $30.73M | $29.72M | $28.92M | $9.63M | $7.49M | $7.60M |
| Current assets | $502.99M | $480.55M | $383.11M | $367.05M | $259.54M | $248.06M | $144.86M | $114.58M |
| PP&E, net | $8.56M | $7.85M | $6.17M | $5.96M | $4.35M | $1.64M | $1.73M | $1.83M |
| Goodwill | $30.00M | $30.00M | $30.00M | $30.00M | $17.52M | — | — | — |
| Intangibles | $348.17M | $358.47M | $368.77M | $379.07M | $390.01M | $1.74M | $1.79M | $1.84M |
| Total assets | $917.75M | $904.05M | $815.64M | $826.14M | $750.86M | $252.60M | $149.58M | $118.85M |
| Current liabilities | $207.29M | $187.40M | $128.78M | $174.27M | $133.64M | $31.71M | $34.39M | $33.84M |
| Long-term debt | — | — | — | $150,000 | $150.00M | — | — | — |
| Total debt | — | — | — | $150,000 | $150.00M | — | — | — |
| Total liabilities | $456.04M | $443.22M | $378.59M | $420.83M | $376.73M | $31.97M | $34.69M | $34.19M |
| Shareholders' equity | $461.71M | $460.83M | $437.05M | $405.31M | $374.13M | $220.63M | $114.89M | $84.66M |
| Net debt | — | — | — | -$144.69M | $101.51M | — | — | — |
| Shares outstanding | 79.48M | 77.67M | 78.40M | 79.26M | 78.35M | 74.62M | 67.71M | 64.41M |
| Cash flow statement | ||||||||
| Operating cash flow | $89.70M | $86.24M | $42.38M | $94.46M | $30.86M | $29.99M | $19.74M | -$5.61M |
| Capital expenditure | $1.91M | $561,000 | $729,000 | $1.72M | $506,000 | $24,000 | $10,000 | $9,869 |
| Free cash flow | $87.79M | $85.68M | $41.65M | $92.74M | $30.35M | $29.97M | $19.73M | -$5.62M |
| Investing cash flow | -$1.91M | -$561,000 | $2.96M | $3.30M | -$291.32M | -$20.21M | -$195,000 | -$304,161 |
| Financing cash flow | $10.67M | -$7.07M | -$12.10M | -$1.41M | $150.53M | $83.24M | $6.09M | $11.28M |
| Depreciation & amortization | $10.53M | $10.54M | $10.54M | $294,096 | $3.79M | $163,000 | $162,000 | $81,727 |
| Stock-based compensation | $3.94M | $4.08M | $4.58M | $3.59M | $4.07M | $2.68M | $3.50M | $1.19M |
| Share buybacks | $0 | $6.39M | $11.09M | — | $0 | $0 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.